11 April 2013
BIND Therapeutics, a biotech asset of Russia’s Rusnano, has inked an agreement with Pfizer, a global pharma major, on the joint development and sales of innovation drugs, including cancer ones, Rusnano announced .
Under the terms of cooperation, the partners will tap into BIND Therapeutics’ Accurins proprietary technology platform enabling targeted delivery of drugs to cells and tissues. Both companies will also team up in conducting preclinical trial testing.
“Pfizer will have the exclusive option to pursue development and commercialization of the Accurins selected by its team… and if Pfizer exercises its option, Pfizer will have responsibility for development and commercialization of the selected Accurins. BIND could receive up-front and development milestone payments totaling approximately $50m and approximately $160m in regulatory and sales milestone payments for each Accurin commercialized as well as tiered royalties on potential future sales,” Rusnano said.
BIND Therapeutics is the new name of what was formerly known as BIND Biosciences.
14 March 2024
26 February 2024
NovaMedica team wishes you a Merry Christmas and a Happy New Year!
26 December 2023
Russian drug for the treatment of viral hepatitis will be exempt from duty in Mongolia
24 April 2024
PM Mishustin: “We need to increase the production of vital and essential drugs in Russia”
24 April 2024
The Future of Pharmacy: How Advancements in Technology Are Transforming the Field
23 April 2024
Analysis Forecasts Up to 16.5% of Population Will Have Chronic Kidney Disease by 2032
23 April 2024